Welgene Biotech Co.Ltd.
Welgene Biotech Co.,Ltd. engages in the trade of biotechnology-related instruments, reagents, and biotechnology testing services. The company offers research services, including generation, PacBio third generation sequencing; microarray, protein body analysis; nucleic acid extraction/QC, single cell experimental, and bioinformatics analysis services. It also provides reagents, medical consumables… Read more
Welgene Biotech Co.Ltd. - Asset Resilience Ratio
Welgene Biotech Co.Ltd. (6661) has an Asset Resilience Ratio of 11.67% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Welgene Biotech Co.Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Welgene Biotech Co.Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$64.70 Million | 11.67% |
| Total Liquid Assets | NT$64.70 Million | 11.67% |
Asset Resilience Insights
- Moderate Liquidity: Welgene Biotech Co.Ltd. has 11.67% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Welgene Biotech Co.Ltd. Industry Peers by Asset Resilience Ratio
Compare Welgene Biotech Co.Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Welgene Biotech Co.Ltd. (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Welgene Biotech Co.Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 10.35% | NT$54.70 Million | NT$528.25 Million | +8.59pp |
| 2023-12-31 | 1.77% | NT$9.70 Million | NT$548.16 Million | -11.95pp |
| 2022-12-31 | 13.72% | NT$59.77 Million | NT$435.71 Million | +7.95pp |
| 2021-12-31 | 5.77% | NT$24.49 Million | NT$424.54 Million | -0.27pp |
| 2020-12-31 | 6.04% | NT$21.77 Million | NT$360.29 Million | +0.65pp |
| 2019-12-31 | 5.39% | NT$22.77 Million | NT$422.25 Million | +0.81pp |
| 2018-12-31 | 4.58% | NT$16.60 Million | NT$362.34 Million | -2.33pp |
| 2017-12-31 | 6.91% | NT$21.57 Million | NT$312.00 Million | +5.23pp |
| 2016-12-31 | 1.68% | NT$4.65 Million | NT$276.03 Million | -13.45pp |
| 2015-12-31 | 15.14% | NT$42.61 Million | NT$281.50 Million | +14.02pp |
| 2014-12-31 | 1.12% | NT$2.49 Million | NT$222.51 Million | -- |